Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $151.8 million versus the consensus estimate of $151.83 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.